Cargando…

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer

Dasatinib (DAS) is a multikinase inhibitor that acts on several signaling kinases. DAS is used as a second-line treatment for chronic accelerated myeloid and Philadelphia chromosome-positive acute lymphoblastic leukemia. The therapeutic potential of DAS in other solid tumours is under evaluation. As...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niza, Enrique, Noblejas-López, María del Mar, Bravo, Iván, Nieto-Jiménez, Cristina, Castro-Osma, José Antonio, Canales-Vázquez, Jesús, Lara-Sanchez, Agustín, Galán Moya, Eva M., Burgos, Miguel, Ocaña, Alberto, Alonso-Moreno, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955794/ https://www.ncbi.nlm.nih.gov/pubmed/31888247 http://dx.doi.org/10.3390/nano9121793

Ejemplares similares

Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy
por: Niza, Enrique, et al.
Publicado: (2019)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
por: Cimas, Francisco J., et al.
Publicado: (2020)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment
por: Niza, Enrique, et al.
Publicado: (2021)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
por: Ocana, Alberto, et al.
Publicado: (2017)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF(4)] in Breast Cancer Models
por: Corrales Sánchez, Veronica, et al.
Publicado: (2019)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
por: Nieto, Celia, et al.
Publicado: (2020)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
por: Le Scodan, Romuald, et al.
Publicado: (2011)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
por: Juan, Alberto, et al.
Publicado: (2022)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
por: Niikura, Naoki, et al.
Publicado: (2023)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
por: Nieto-Jimenez, Cristina, et al.
Publicado: (2020)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
por: Mihaljevic, Andre, et al.
Publicado: (2009)

Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report
por: Papageorgiou, Konstantinos I, et al.
Publicado: (2009)

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
por: Wolf, Benita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ar1rah6s0vuu64kugoiub5riv